BTK and B-cell chronic lymphocytic leukemia: Nevertheless, as the aggressiveness of B-cell malignancies can be highly variable between tumor types or even between patients of a same tumor type such as CLL [33, 34], a population of patients where BTK turnovers uniformly distributed from 12 h to 120 h was simulated and could adequately describe the proportion of patients with more than 90% BTKOCC,7 seen in Phase 1/2 study PCYC-04753 and Phase 2 study PCYC-1102 (Fig. 3).